CRISPR-Based Detection of Sars-Cov-2 By Detectr

At Mammoth Biosciences, we are harnessing the natural diversity of CRISPR for a new purpose: a programmable diagnostics platform, called DETECTR™, that can identify virtually any genetic sequence of interest. During the COVID-19 pandemic, Mammoth reconfigured its DETECTR™ platform to identify SARS-CoV-2. Our DETECTR™ technology uses Mammoth’s proprietary Cas enzymes to detect the presence of SARS-CoV-2 after isothermal amplification. These assays leverage the flexibility of CRISPR diagnostics to function in a variety of testing environments including centralized laboratories and in point-of-need environments. This work demonstrated not only the sensitivity and specificity of CRISPR diagnostics, but also the speed at which new molecular diagnostics can be developed using our DETECTR™ technology. We continue to expand and enhance the functionality of our CRISPR diagnostic platform through the development of new protein systems including members of the Cas12, Cas13, and Cas14 families.